Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe record history now shows the latest revision, updating from v3.6.3 to v3.6.4.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedA new revision entry v3.6.3 was added to the study record history, and the previous revision v3.6.2 was removed. This reflects an update to the record's version in the history log.SummaryDifference0.1%

- Check36 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2, indicating a platform update. There is no visible impact on the study history entries or data.SummaryDifference0.1%

- Check50 days agoChange DetectedRecruitment status updated to 'No longer looking for participants,' indicating termination due to low enrollment. The study record version updated to v3.6.0, replacing the previous v3.5.5.SummaryDifference0.4%

- Check57 days agoChange DetectedA new revision tag v3.5.5 is added to the page history, replacing v3.5.4, indicating an update to the record.SummaryDifference0.1%

- Check79 days agoChange DetectedAdded a new revision entry v3.5.4 to the record history. The previous revision v3.5.3 was removed from the history.SummaryDifference0.1%

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.